Abstract
Preclinical research has identified an array of ion channels in sensory neurons involved in the generation and transduction of pain as potential targets for pharmacological intervention. Paramount among these new targets is the family of thermosensitive transient receptor potential channels, referred to as “thermoTRPs”. We detect a wide range of noxious stimuli via a limited number (as of today, six) of thermoTRP channels, four of which (TRPV1-TRPV4) respond to heat and two (TRPA1 and TRPM8) are sensitive to cold. Targeting these thermoTRP channels represents a new and logical strategy in pain relief. Unlike traditional analgesic drugs that either suppress inflammation (e.g. NSAIDs and COX-2 inhibitors) or block pain transmission (e.g. opiates), TRP channel inhibitors aim to prevent pain by blocking a receptor where pain is generated. The archetypal thermoTRP is the vanilloid (capsaicin) receptor TRPV1. TRPV1 has a dynamic threshold of activation. Agents in inflammatory soup, including endogenous TRPV1 agonists (so-called “endovanilloids”), act in concert to reduce the heat activation threshold of TRPV1. In patients, the expression of TRPV1 is upregulated in a number of painful inflammatory disorders. TRPV1 as a pain target has been validated by genetic deletion and pharmacological inhibition experiments. This area of drug development has been moving rapidly. It took less than a decade from the cloning of TRPV1 to clinical trials with potent small molecule TRPV1 antagonists. This review evaluates current evidence that supports particular TRP channels as targets for novel analgesic drugs, along with potential adverse effects that may limit drug development.
Keywords: Temperature-sensitive transient receptor potential channels, “thermoTRPs”, transient receptor potential, vanilloid subfamily channels (TRPV), vanilloid (capsaicin) receptor TRPV1, ankyrin subfamily member 1, TRPA1, melastatin subfamily member 8
Current Pharmaceutical Design
Title: TRP Channels and Pain
Volume: 15 Issue: 15
Author(s): Daniel N. Cortright and Arpad Szallasi
Affiliation:
Keywords: Temperature-sensitive transient receptor potential channels, “thermoTRPs”, transient receptor potential, vanilloid subfamily channels (TRPV), vanilloid (capsaicin) receptor TRPV1, ankyrin subfamily member 1, TRPA1, melastatin subfamily member 8
Abstract: Preclinical research has identified an array of ion channels in sensory neurons involved in the generation and transduction of pain as potential targets for pharmacological intervention. Paramount among these new targets is the family of thermosensitive transient receptor potential channels, referred to as “thermoTRPs”. We detect a wide range of noxious stimuli via a limited number (as of today, six) of thermoTRP channels, four of which (TRPV1-TRPV4) respond to heat and two (TRPA1 and TRPM8) are sensitive to cold. Targeting these thermoTRP channels represents a new and logical strategy in pain relief. Unlike traditional analgesic drugs that either suppress inflammation (e.g. NSAIDs and COX-2 inhibitors) or block pain transmission (e.g. opiates), TRP channel inhibitors aim to prevent pain by blocking a receptor where pain is generated. The archetypal thermoTRP is the vanilloid (capsaicin) receptor TRPV1. TRPV1 has a dynamic threshold of activation. Agents in inflammatory soup, including endogenous TRPV1 agonists (so-called “endovanilloids”), act in concert to reduce the heat activation threshold of TRPV1. In patients, the expression of TRPV1 is upregulated in a number of painful inflammatory disorders. TRPV1 as a pain target has been validated by genetic deletion and pharmacological inhibition experiments. This area of drug development has been moving rapidly. It took less than a decade from the cloning of TRPV1 to clinical trials with potent small molecule TRPV1 antagonists. This review evaluates current evidence that supports particular TRP channels as targets for novel analgesic drugs, along with potential adverse effects that may limit drug development.
Export Options
About this article
Cite this article as:
Cortright N. Daniel and Szallasi Arpad, TRP Channels and Pain, Current Pharmaceutical Design 2009; 15 (15) . https://dx.doi.org/10.2174/138161209788186308
DOI https://dx.doi.org/10.2174/138161209788186308 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Intestinal Absorption Mechanism of Gabapentin Makes it Appropriate for Gastroretentive Delivery
Current Clinical Pharmacology Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment
Current HIV Research Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis
Current Drug Therapy Melatonin in Antinociception: Its Therapeutic Applications
Current Neuropharmacology Patent Selections
Recent Patents on Drug Delivery & Formulation Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets Genetic Analysis of Aldose Reductase in Diabetic Complications
Current Medicinal Chemistry The Role of 5-HT1A Receptors in Research Strategy for Extensive Pain Treatment
Current Topics in Medicinal Chemistry Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology RAGE, Diabetes, and the Nervous System
Current Molecular Medicine Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Physicians’ Perception About Use of Vitamin B12 in the Treatment or Prevention of Diabetic Neuropathy: A Cross-sectional Survey in Saudi Arabia
Current Diabetes Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry